Status:
COMPLETED
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Lead Sponsor:
University Hospital, Caen
Conditions:
Cancer
Eligibility:
All Genders
Brief Summary
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data ar...
Detailed Description
Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of hypertension AE related to PARPi.
Eligibility Criteria
Inclusion
- case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
- patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib, pamiparib, fluzoparib (none).
Exclusion
- chronology not compatible between the PARPi and adverse event
Key Trial Info
Start Date :
February 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2022
Estimated Enrollment :
2336 Patients enrolled
Trial Details
Trial ID
NCT04774406
Start Date
February 24 2021
End Date
September 1 2022
Last Update
June 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alexandre Joachim
Caen, Basse Normandie, France, 14000